Discover the slimmest video bronchoscopes for thin-lumen diagnostics with their unique *insertion tube rotation function* and wide angulation.

**OLYMPUS BF-P190**
With its slim outer diameter and its standard 2.0 mm instrument channel, which allows for the use of a wide range of EndoTherapy instruments, the BF-P190 is the new flagship model for diagnostics in the narrow bronchial airways. The diagnostic versatility is underlined by its compatibility with radial ultrasound miniature probes as well as when used in combination with the GuideSheathKit.

**OLYMPUS BF-XP190**
The new ultraslim highlight of the EVIS EXERA III endoscope family provides stunning image quality while offering compatibility with 1.2 mm EndoTherapy instruments. Given its ultraslim specifications, the BF-XP190 is the ideal bronchoscope for accessing the thin bronchi of the adult lung periphery and for pediatric bronchoscopy.

For more information, please contact your OLYMPUS sales representative or visit [www.olympus-europa.com](http://www.olympus-europa.com).
Submission
Manuscripts written in English should be submitted using the online submission website at:

www.karger.com/res

Should you experience any problems with your submission, please contact:

res@karger.com

S. KARGER AG
Editorial Office 'Respiration'
PO Box
CH–4009 Basel (Switzerland)

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Conditions

All manuscripts are subject to an editorial process involving the Editor-in-Chief, an Associate Editor and reviewers. Notification can be expected within two months from the date of receipt. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Respiration and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Clinical Trials: In accordance with the recommendations of the International Committee of Medical Journal Editors, the journal requires that all clinical trials having commenced on or after 1 July 2005 be registered in a public trial registry accessible free of charge. Please consult http://www.icmje.org/index.html#clin_trials for further details. Respiration has implemented the expanded definition stating that 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

The journal consists of the following sections:

1. Thematic Review Series
2. Editorial Comments
3. Clinical Investigations
4. Interventional Pulmonology
5. Basic Science Investigations
6. The Eye Catcher
7. Novel Insights from Clinical Practice
8. What Is Your Diagnosis?
9. Reviews
10. Guidelines
11. Clinico-Pathological Conferences
12. Letters to the Editor

Reviews: Invited reviews, if accepted, are not subject to page charges. Unsolicited reviews may also be submitted for consideration.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in respiratory medicine are also welcome. Letters to the Editor should be no longer than one printed page.

Eye Catchers: Maximum 1 printed page. Text may not exceed 250 words to allow sufficient space for pictorial material, which is the main object of an Eye Catcher. Maximum 2 references and 2–5 keywords.

Novel Insights from Clinical Practice (formerly Case Reports): Maximum 7 authors. The publication space available for case reports is very limited. The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. Highlighted boxes containing one or two bullet points on 'Established facts' (what is already known) and 'Novel insights' (what new information has been gained) are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation. The text per box should be limited to 1–2 very short sentences. The manuscript should be presented with an abstract (unstructured, max. 200 words), followed by introduction, case report and discussion. Maximum 3 figures.

What Is Your Diagnosis?: Select catchy title not disclosing the diagnosis. Page 1: Case report and 1–2 illustrations and the question 'What Is Your Diagnosis?'. Page 2: The diagnosis followed by a short description of what diagnostic procedures were done to reach the diagnosis and the discussion with references. Maximum 15 references and include 3–5 key words.

Guidelines: Consensus Guidelines are welcome from working groups to provide guidance in key and emerging areas in all fields of respiratory medicine. Such guidelines are also subject to a reviewing process.

Patient Consent: This is required for ALL articles containing personal information about the patient submitted for publication in the following sections: Novel Insights from Clinical Practice What Is Your Diagnosis? Eye Catcher

Signed patient consent must be obtained from the patient, guardian or next of kin (or a statement that the patient was not alive at the time of writing) and submitted along with the manuscript. For Patient Consent Form see www.karger.com/res_Guidelines

Arrangement

Pages should be numbered throughout the manuscript text.

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full words: Abstract Each paper needs an abstract of up to 250 words. Abstracts of papers submitted for publication in the sections Clinical Investigations, Basic Science Investigations, Interventional Pulmonology, and Technical Notes should be structured as follows:

Background: What is the major motive that prompted the study?

Objectives: What is the purpose of the study?

Methods: How was the study done?

Results: Most important findings.

Conclusions: Most important conclusions.

Introduction

What is the main question? State your considerations leading to the formulation of this question.

Material and Methods

Prior approval of an Institutional Review Board (IRB) is required for all investigations involving human subjects and animals. Animal experimentation must be performed according to the Helsinki Declaration.

Study design: Provide a short survey of the tests or experiments. Include the independent variable(s) manipulated, the dependent variable(s) measured and all controls.

Methods: Describe methods and apparatus in detail. Provide references and brief description of methods already published. Identify drugs and chemicals, including generic name, dosage and administration. Describe the pre-study condition of patients or animals.

Analysis: Define the variables. Use statistical analysis that is appropriate for the study. Describe statistical methods used for each analysis; provide references for tests that are not well known.

Results

A concise report of important results only. Use figures and tables for the presentation of data; summarize the most important observations in the text. Start and end dates of the study must be indicated (from ... to, preferably exact dates, but at least months and year(s)).

The Guidelines for Authors are available at:

www.karger.com/res_Guidelines
Guidelines for Authors

Discussion
Summarize main results and make sure you can answer the question asked in the introduction, briefly supporting the answer with the relevant results. Explain and defend the answer, comment on contradictory or unexpected results and discrepancies with previous findings. Elaborate on new and important aspects of the study.

Acknowledgements
Use this section to name persons who have contributed to the article, but whose contributions do not justify authorship.

Footnotes
Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and Illustrations
Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at www.karger.com/res_Guidelines).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished square brackets]. Material submitted for publication outside Europe where Respiration is read have not accepted the SI System, authors using SI Units should add the conventional units in parentheses, for example: \( \rho_O = 10 \text{ kPa} \) (75 mm Hg).

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpg).

Page Charges
There are no page charges for papers of 4 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is 2500 words. The allotted size of a paper is equal to approx. 12 manuscript pages (including tables, illustrations and references).

Author’s Choice
Karger’s Author’s Choice feature broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost as grant allocation. More information can be found at www.karger.com/author_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo.

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copylefting and design improvements as well as citation links.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

E-publish
All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors’ approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Financial Disclosure and Conflicts of Interest
Authors must disclose any and all financial involvement in any organization with a direct financial interest in the subject discussed in the submitted manuscript. Any conflict of interest for a given manuscript must be dealt with according to the statement of the International Committee of Medical Journal Editors (the ‘Vancouver Group’) (Lancet 1993;341:742).

Further Information
For any further details please contact the Editorial Department (Respiration, Fax +41 61 306 14 34).

KARGER
© 2014 S. Karger AG, Basel
E-Mail karger@karger.com
The Guidelines for Authors are available at:
www.karger.com/res_Guidelines

Downloaded by: 54.191.40.80 - 9/17/2017 2:44:43 AM
General Information

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Print or Online
CHF 163.00
EUR 134.00
USD 163.00

Print+Online combined
CHF 259.00
EUR 212.00
USD 259.00

postage and handling (added to print and print+online)
EUR 72.00
USD 117.60

Institutional subscription:
CHF 2692.00
EUR 2206.00
USD 2692.00

postage and handling (added to print and print+online)
EUR 111.00
USD 147.00

Discount subscription prices:
USD 117.60
EUR 72.00
USD 147.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive Danvers, MA 01923 (USA). A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, PO Box CH–4009 Basel (Switzerland).

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Discount subscription prices:
USD 117.60
EUR 72.00
USD 147.00

Change of Address:
Both old and new address should be sent to the subscription source.

KARGER © 2014 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com

The Journal Home Page is available at:
www.karger.com/res
Contents

See the journal website for contents
45th Union World Conference on Lung Health
BARCELONA, SPAIN • 28 OCTOBER-1 NOVEMBER 2014
www.worldlunghealth.org

International Union Against Tuberculosis and Lung Disease
Union Internationale Contre la Tuberculose et les Maladies Respiratoires
Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias
ILYA MECHNIKOV MEMORIAL LECTURE
Allan Goldstein  The George Washington University School of Medicine, Washington, USA
Thymosins in health and disease

PAUL EHRLICH MEMORIAL LECTURE
Michal Schwartz  Weizmann Institute of Science, Rehovot, Israel
Circulating immune cells play a key role in brain maintenance and repair: The brain's choroid plexus as the nexus between the brain and immune system

KEYNOTE LECTURE
Sami Bahna  Louisiana State University Health Sciences Center, Shreveport, LA, USA
You can have allergy to food and eat it too

SUPPORTED BY
representatives of
World Immunopathology Organization (WIPO)
World Allergy Organization (WAO)
International Union of Immunological Societies (IUIS)
International Association of Asthmology (INTERASMA)
European Academy of Allergy and Clinical Immunology (EAACI)
European Respiratory Society (ERS)
European Federation of Immunological Societies (EFIS)
American College of Allergy, Asthma & Immunology (ACAAI)
American Academy of Allergy, Asthma and Immunology (AAAAAI)
Asian Pacific Association of Allergy, Asthma & Clinical Immunology (APAAACI)
Asian Pacific Respirology Society (APRS)

WAO WORLD ALLERGY TRAINING SCHOOL (WATS)

EAACI – CIS JOINT SYMPOSIUM

CONGRESS SECRETARIAT
WORLD IMMUNOPATHOLOGY ORGANIZATION

(7-495) 735-1414
Fax  (7-495) 735-1441
E-mail  info@wipocis.org (Registration, Accommodation, Tours)
        wipocis@mail.ru (Abstracts, Congress Program)

www.wipocis.org
A complete record of recent progress in cardiology
This high-yield reference book focuses on the clinical, technical, and pathological aspects of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). It reviews cover all aspects of EBUS-TBNA, including the clinical perspective, technical aspects of the procedure, and cytomorphology of common and uncommon entities, as well as highlights diagnostic challenges. Each chapter features a multitude of full-color high-resolution images and includes key references to the current literature in the field. Additionally, reference tables and informative figures highlight the salient points. The book is unique in that it is written by experienced thoracic surgeons, pulmonary medicine physicians, and cytopathologists who use EBUS-TBNA in a large medical center.

This publication is of interest to individuals learning and practicing cytopathology, in addition to clinicians practicing pulmonary/thoracic medicine or surgery. In short, it provides important pearls of wisdom to create a comprehensive reference for all physicians involved with EBUS-TBNA.
A collaborative project between WABIP and Pfizer®

The WABIP is proud to present a series of three non-CME webcasts using a clinical stem, patient centered case simulation format designed for a global audience of health care providers caring for patients with nonsmall cell lung cancer (NSCLC).

The purpose of these webcasts is to increase knowledge regarding the appropriate selection, acquisition, and processing of cytology and histology samples from patients with known or suspected lung cancer.

FEATURES:
• Accessible Anytime, Anywhere
• Full Audio Narration
• Expert Video Commentaries
• Expert Audio Commentaries
• Interactive Q&A

In collaboration with

Pfizer Oncology

Only on WABIPACADEMY.com
Cover illustration
Clockwise from top: Ultrasound image of a solid peripheral lesion; courtesy of D. Gompelmann, Heidelberg. A 78-year-old man with clinical increasing dyspnoea; lung sonography reveals irregular pleural surface and multiple B-lines; corresponding chest computed tomography shows typical features of idiopathic pulmonary fibrosis; courtesy of A. Reissig, Heidelberg. Ultrasound of the chest in pulmonary edema showing multiple, laser-like reverberations, so called B-lines; courtesy of M. Kreuter, Heidelberg. Doppler examination of pneumonia with a lovely artefact; courtesy of F.J.F. Herth, Heidelberg.